blog

Perfuse Therapeutics Reports Positive Phase 1/2a Results for PER-001 Glaucoma Implant In a significant milestone for glaucoma treatment, Perfuse Therapeutics has announced encouraging results from its Phase 1/2a clinical trial for the PER-001 glaucoma implant. The novel device, designed to provide sustained intraocular pressure (IOP) reduction, demonstrated both safety and efficacy in early-stage testing, offering […]

BVI Medical’s Leos™ Laser Endoscopy System Receives FDA 510(k) Clearance The medical technology landscape continues to evolve with groundbreaking innovations, and BVI Medical is at the forefront of this transformation. The company has recently achieved a significant milestone as its Leos™ Laser Endoscopy System has received FDA 510(k) clearance. This approval marks a pivotal moment

Public Lacks Awareness of Glaucoma and Cataracts Risks Eye health is often overlooked until problems arise, yet conditions like glaucoma and cataracts can lead to severe vision impairment or even blindness if left untreated. Shockingly, many people remain unaware of the risks, symptoms, and preventive measures associated with these common eye diseases. Raising awareness is

Glaucoma Treatment Market Growth 2034: FDA Approvals, Therapies, and Key Players The glaucoma treatment market is poised for significant growth by 2034, driven by advancements in therapies, increasing FDA approvals, and the emergence of innovative solutions from key industry players. Glaucoma, a leading cause of irreversible blindness, affects millions worldwide, creating a pressing need for

# **Glaucoma Eye Drops Market Growth, Analysis, and Forecast to 2025** ## **Introduction** Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. With the increasing prevalence of this condition, the demand for effective treatments, particularly glaucoma eye drops, has surged. The **glaucoma eye drops market** is projected to experience significant growth

Remidio’s AI Tools for Glaucoma and AMD Secure CDSCO Approval The healthcare technology landscape is evolving rapidly, and artificial intelligence (AI) is playing a pivotal role in transforming diagnostics and treatment. In a significant milestone, Remidio Innovative Solutions, a pioneer in AI-driven ophthalmic diagnostics, has secured approval from the Central Drugs Standard Control Organization (CDSCO)

# **50 Years of Ophthalmology Breakthroughs: Experts Reflect on Innovations** ## **Introduction** Over the past five decades, ophthalmology has undergone a revolution, transforming the way we diagnose, treat, and prevent eye diseases. From groundbreaking surgical techniques to cutting-edge diagnostic tools, these advancements have restored vision for millions and reshaped the future of eye care. In

Comprehensive Guide to Screening, Diagnosing, and Treating Open Angle Glaucoma Open-angle glaucoma is one of the most common forms of glaucoma, affecting millions of people worldwide. Often called the “silent thief of sight,” it progresses slowly and without noticeable symptoms until significant vision loss occurs. Early detection and proper treatment are crucial to preventing irreversible

Early Signs and Treatment Options for Glaucoma You Should Know Glaucoma is a serious eye condition that can lead to irreversible vision loss if not detected and treated early. Often referred to as the “silent thief of sight,” glaucoma progresses slowly and may not present noticeable symptoms until significant damage has occurred. Understanding the early

Remidio’s AI Tools for Glaucoma and AMD Gain CDSCO Approval The healthcare technology landscape is evolving rapidly, and artificial intelligence (AI) is at the forefront of this transformation. In a significant milestone, Remidio, a pioneering med-tech company, has secured approval from the Central Drugs Standard Control Organization (CDSCO) for its AI-powered diagnostic tools designed to